Program
Pramipexole
Also written as “pramipexole”, “Pramipexole Dihydrochloride” and “Pramipexole Immediate Release”.
Its studies are mostly in Parkinson Disease · Restless Legs Syndrome · Tourette Syndrome · Depressive Disorder, Major · Obsessive-Compulsive Disorder, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 360 open or running | phase 4since Sep 2, 2005 | Aug 22, 2005 | none ahead |
| Teva Pharmaceutical Industries | 30 open or running | phase 4since Nov 10, 2006 | Nov 10, 2006 | none ahead |
| Chase Therapeutics | 11 open or running | phase 2since Jul 5, 2018 | Jul 5, 2018 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 1since May 8, 2007 | May 8, 2007 | none ahead |
| Haisco Pharmaceutical Group | 10 open or running | phase 1since Apr 2, 2026 | Apr 2, 2026 | none ahead |
| Novartis | 10 open or running | phase 4since Aug 23, 2012 | Aug 23, 2012 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 25 studies since Aug 22, 2005.
- Mar 27, 2008Phase 3 study in Restless Legs SyndromeBoehringer Ingelheim · NCT00654498 · 306 enrolled · China
- May 19, 2008Phase 3 study in Tourette SyndromeBoehringer Ingelheim · NCT00681863 · 45 enrolled · United States, Germany
- May 29, 2008Phase 2 study in FibromyalgiaBoehringer Ingelheim · NCT00689052 · 61 enrolled · United States
- Feb 22, 20102 phase 1 studies in HealthyTeva Pharmaceutical Industries · NCT01074463, NCT01074450
- Aug 30, 2010Phase 3 study in Parkinson DiseaseBoehringer Ingelheim · NCT01191944 · 475 enrolled · China
- Oct 1, 2010Phase 1 study in HealthyBoehringer Ingelheim · NCT01214109 · 24 enrolled · China
- Aug 23, 2012Novartis's first study: phase 4 study in Parkinson DiseaseNew to NovartisNovartis · NCT01673724 · 121 enrolled · Korea, Republic of
- Jun 20, 20142 phase 3 studies in Parkinson DiseaseBoehringer Ingelheim · NCT02172573, NCT02177357
- Sep 4, 2014Phase 4 study in Parkinson DiseaseBoehringer Ingelheim · NCT02233023 · 705 enrolled
- Oct 9, 20143 phase 1 studies in HealthyBoehringer Ingelheim · NCT02262546, NCT02261103, NCT02264132
- Apr 11, 2018Phase 4 study in Parkinson DiseaseBoehringer Ingelheim · NCT03521635 · 98 enrolled · China
- Jul 5, 2018Chase Therapeutics's first study: phase 2 study in Depressive Disorder, MajorNew to Chase TherapeuticsChase Therapeutics · NCT03642964 · 24 enrolled · United States
- Apr 2, 2026Haisco Pharmaceutical Group's first study: phase 1 study in HealthyNew to Haisco Pharmaceutical GroupHaisco Pharmaceutical Group · NCT07519278 · 49 enrolled · China
- Jul 22, 2026Phase 1 study in HealthyBoehringer Ingelheim · NCT07727785 · 25 enrolled · Germany
TargetBeta
“D2-like dopamine receptor agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| rotigotinerule | UCB | phase 4 | 64 |
Studies
All 43 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07727785Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Sep 10, 2026 | 25 |
| NCT07519278Healthy · China | 1 | Completed | Haisco Pharmaceutical Group | Apr 11, 2017 | 49 |
| NCT03642964Depressive Disorder, Major · United States | 2 | Active, not recruiting | Chase Therapeutics | Dec 30, 2025 | 24 |
| NCT03521635Parkinson Disease · China | 4 | Completed | Boehringer Ingelheim | Jan 7, 2020 | 98 |
| NCT02264132Healthy | 1 | Completed | Boehringer Ingelheim | Nov 2006 | 24 |
| NCT02262546Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2007 | 60 |
| NCT02261103Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2006 | 39 |
| NCT02233023Parkinson Disease | 4 | Completed | Boehringer Ingelheim | Jun 2000 | 705 |
| NCT02177357Parkinson Disease | 3 | Completed | Boehringer Ingelheim | Jan 2000 | 150 |
| NCT02172573Parkinson Disease | 3 | Completed | Boehringer Ingelheim | Jul 2000 | 315 |
| NCT01673724Parkinson Disease · Korea, Republic of | 4 | Completed | Novartis | May 23, 2016 | 121 |
| NCT01214109Healthy · China | 1 | Completed | Boehringer Ingelheim | Jan 2011 | 24 |
| NCT01191944Parkinson Disease · China | 3 | Completed | Boehringer Ingelheim | Jan 2012 | 475 |
| NCT01074463Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Mar 2005 | 24 |
| NCT01074450Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Mar 2005 | 24 |
| NCT00689052Fibromyalgia · United States | 2 | Terminated | Boehringer Ingelheim | Nov 2008 | 61 |
| NCT00681863Tourette Syndrome · United States, Germany | 3 | Terminated | Boehringer Ingelheim | Oct 2009 | 45 |
| NCT00654498Restless Legs Syndrome · China | 3 | Completed | Boehringer Ingelheim | Jun 2009 | 306 |
| NCT00601523Parkinson Disease · United States, Austria, Czech Republic and more | 3 | Completed | Boehringer Ingelheim | Jun 2010 | 511 |
| NCT00577460Parkinson Disease · Austria, Czech Republic, Hungary and more | 3 | Completed | Boehringer Ingelheim | Jun 2010 | 391 |
| NCT00560508Parkinson Disease · Japan | 3 | Completed | Boehringer Ingelheim | Nov 2009 | 112 |
| NCT00558467Tourette Syndrome · United States, Germany | 2 | Completed | Boehringer Ingelheim | Jun 2009 | 63 |
| NCT00558025Parkinson Disease · France, Germany, Netherlands | 3 | Completed | Boehringer Ingelheim | May 2008 | 156 |
| NCT00479401Parkinson Disease · United States, Argentina, Austria and more | 3 | Completed | Boehringer Ingelheim | Nov 2008 | 539 |
| NCT00472199Restless Legs Syndrome · Austria, Belgium, Finland and more | 4 | Completed | Boehringer Ingelheim | Jul 2008 | 331 |
| NCT00471588Obsessive-Compulsive Disorder · United Kingdom | 1 | Completed | GlaxoSmithKline | Dec 2007 | 52 |
| NCT00466167Parkinson Disease · Austria, Czech Republic, Hungary and more | 3 | Completed | Boehringer Ingelheim | Nov 2008 | 517 |
| NCT00402233Parkinson Disease · United States | 4 | Completed | Boehringer Ingelheim | Sep 2008 | 312 |
| NCT00399477Parkinson Disease | 4 | Completed | Teva Pharmaceutical Industries | Jul 2007 | 200 |
| NCT00390689Idiopathic Restless Legs Syndrome · Japan | 3 | Completed | Boehringer Ingelheim | Mar 2008 | 154 |
| NCT00375284Restless Legs Syndrome · United States | 4 | Completed | Boehringer Ingelheim | Jul 2007 | 404 |
| NCT00356096Restless Legs Syndrome · Finland, France, Germany and more | 4 | Completed | Boehringer Ingelheim | Jun 2007 | 404 |
| NCT00349531Restless Legs Syndrome · Denmark, Finland, Germany and more | 4 | Completed | Boehringer Ingelheim | May 2007 | 369 |
| NCT00321854Parkinson Disease · United States, Austria, Finland and more | 4 | Completed | Boehringer Ingelheim | Apr 2009 | 535 |
| NCT00297778Parkinson Disease · Austria, Finland, France and more | 4 | Completed | Boehringer Ingelheim | May 2008 | 296 |
| NCT00275457Restless Legs Syndrome · Austria, Germany, Netherlands and more | 3 | Completed | Boehringer Ingelheim | Apr 2004 | 346 |
| NCT00240409Parkinson Disease · China | 3 | Completed | Boehringer Ingelheim | Aug 2004 | 208 |
| NCT00239486Restless Legs Syndrome · Finland | 2 | Completed | Boehringer Ingelheim | Apr 2004 | 109 |
| NCT00152997Restless Legs Syndrome · Japan | 2 | Completed | Boehringer Ingelheim | Dec 2005 | 41 |
| NCT00152958Restless Legs Syndrome · Germany | 3 | Completed | Boehringer Ingelheim | Feb 2005 | 224 |
| NCT00144300Parkinson Disease · United States | 4 | Completed | Boehringer Ingelheim | Sep 2010 | 246 |
| NCT00144209Restless Legs Syndrome · Switzerland | 3 | Completed | Boehringer Ingelheim | Feb 2005 | 58 |
| NCT00133198Restless Legs Syndrome · United States | 3 | Completed | Boehringer Ingelheim | Feb 2005 | 345 |
How it is read
Names in the registry
- “Pramipexole”, 15 entries
- “pramipexole”, 5 entries
- “Pramipexole Dihydrochloride”, 4 entries
- “Pramipexole Immediate Release”, 2 entries
- “Pramipexole Extended Release”, 2 entries
Conditions, from the studies’ own filings
- Parkinson Disease, 19 studies
- Restless Legs Syndrome, 12 studies
- Tourette Syndrome, 2 studies
- Depressive Disorder, Major, 1 study
- Obsessive-Compulsive Disorder, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.